Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Studies to Assess the Safety, Tolerability, and Pharmacokinetics of E2082 in Healthy Male Subjects

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Studies to Assess the Safety, Tolerability, and Pharmacokinetics of E2082 in Healthy Male Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Sep 2018

At a glance

  • Drugs E-2082 (Primary)
  • Indications Epilepsy
  • Focus Pharmacokinetics
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 06 Sep 2018 Planned End Date changed from 6 Mar 2019 to 25 Feb 2019.
    • 06 Sep 2018 Planned primary completion date changed from 20 Feb 2019 to 25 Feb 2019.
    • 21 Aug 2018 Planned End Date changed from 1 Mar 2019 to 6 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top